OINDP developer Nanopharm has announced the appointment of Mark Clement as non-executive Chairman of the Board. Clement has more than 25 years of experience in life sciences and is currently non-executive chairman or director of 6 companies in the industry.
Nanopharm co-Founder and Director Rob Price said, “Mark’s extensive experience in managing Life Science businesses from the perspectives of adviser, founder, investor and Board member, as well as his expertise as a developer of leading service companies including Celsis International, Vectura, and Kuecept, make him an ideal Chairman for Nanopharm.”
Nanopharm Managing Director Jag Shur added, “Mark recognizes Nanopharm’s ability to help the pharmaceutical industry move past the trial-and-error approach to drug development which so often results in failure, and he values the rational scientific strategy we employ to safeguard progression of products into the market. His proven business skills and network will be especially valuable as we are experiencing growing demand for our services.”
Clement said, “I’m delighted to be joining such a vibrant company that has achieved a remarkable amount since inception. I am convinced that its expertise and know how in the areas of orally inhaled and nasal delivered drugs, together with Nanopharm’s proactive approach to problem solving, can play to a far broader range of customers.”
Read the Nanopharm press release.
